Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
Study sponsor: Akebia Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-01-06Actual
Enrollment · participants456Actual
Source updated2025-01-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.